产品名称
Butyrolactone I, A cell-permeable and highly selective inhibitor of cyclin-dependent protein kinases (Cdks) that inhibits cell cycle progression at the G1/S and G1/M transitions.
InChI key
FPVUCBMBMUHRDX-XMMPIXPASA-N
InChI
1S/C24H24O7/c1-14(2)4-6-17-12-15(5-11-19(17)26)13-30-23(29)24(3)20(21(27)22(28)31-24)16-7-9-18(25)10-8-16/h4-5,7-12,25-27H,6,13H2,1-3H3/t24-/m1/s1
assay
≥99% (TLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
protect from light
color
white
shipped in
ambient
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
Cell permeable: yes
Primary Target
p34cdk1/cyclinB
p34cdk1/cyclinB
Product does not compete with ATP.
Reversible: no
Target IC50: 680 nM against Cdk1
Disclaimer
Toxicity: Standard Handling (A)
General description
A cell-permeable and highly selective inhibitor of cyclin-dependent protein kinases (Cdks) that inhibits cell cycle progression at the G1/S and G2/M transitions. Inhibits p34cdk1/cyclinB (Cdk1; IC50 = 680 nM). Also selectively inhibits Cdk2 and Cdk5 kinases. Has little effect on casein kinase I, casein kinase II, EGF receptor kinase, MAP kinase, PKA, and PKC. Shown to prevent the phosphorylation of retinoblastoma protein and H1 histone. Also blocks Fas-induced apoptosis in HL-60 cells and shows antitumor effects on human lung cancer cell lines.
Other Notes
Furukawa, Y., et al. 1996. J. Biol. Chem. 271, 28469.
Nishio, K., et al. 1996. Anticancer Res. 16, 3387.
Kitagawa, M., et al. 1994. Oncogene 9, 2549.
Kitagawa, M., et al. 1993. Oncogene 8, 2425.
Nishio, K., et al. 1996. Anticancer Res. 16, 3387.
Kitagawa, M., et al. 1994. Oncogene 9, 2549.
Kitagawa, M., et al. 1993. Oncogene 8, 2425.
Preparation Note
Following initial thaw, aliquot and freeze (-20°C).
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Alessia Oppezzo et al.
Cell & bioscience, 13(1), 115-115 (2023-06-25)
Hematopoietic stem cells (HSCs) reside in the bone marrow (BM) niche, which includes bone-forming and bone-resorbing cells, i.e., osteoblasts (OBs) and osteoclasts (OCs). OBs originate from mesenchymal progenitors, while OCs are derived from HSCs. Self-renewal, proliferation and differentiation of HSCs
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持